A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...

The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...

Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of ...

A recent investigation by The New York Times revealed that two pharmaceutical companies, Eisai and Eli Lilly, withheld critical genetic risk information from volunteers during clinical trials for ...

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for ...

First the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now they are being found to ...